


February 27<sup>th</sup> 2007

# news release



## Contract signed Friday 23 February

In searching for novel schizophrenia susceptibility genes and drug targets, two Dutch universities, Radboud University Nijmegen and Leiden University, and the Danish pharmaceutical company Lundbeck, have teamed up in a four year research programme. During the four year research term, the Dutch teams led by Gerard Martens (Radboud University) and Ron de Kloet (Leiden University), together with the Lundbeck researchers will attempt to

further characterize and identify novel drug targets based on rodent and human studies. The studies will focus on novel susceptibility genes for schizophrenia and derived drug targets which eventually could lead to antipsychotics with entirely new modes of action. A number of research disciplines will be integrated in the programme spanning from molecular genetics to in vivo pharmacology and later on medicinal chemistry.

jointly shaping the future of medicines



**TI PHARMA**

PO Box 142 2300 AC Leiden The Netherlands T + 31(0) 71 5271419 F + 31(0) 71 5271415 [www.tipharma.com](http://www.tipharma.com)